Current status and prospects of breast cancer imaging-based diagnosis using artificial intelligence.

Breast imaging has several modalities, each unique in terms of its imaging position, evaluation index, and imaging method. Breast diagnosis is made by combining a large number of past imaging features with the clinical course and histological findings. Artificial intelligence (AI), which extracts the features from image data and evaluates them based on comprehensive analysis, has been making rapid progress in this regard. Many previous studies have demonstrated the usefulness and development potential of AI, such as machine learning and deep learning, in breast imaging. However, despite studies showing the good performance of AI models, their overall utilization remains low, since a large amount of diverse imaging data is required, and prospective verification is necessary to prove its high reproducibility and robustness. Sharing information and collaborating with multiple institutions to collect and verify images of different conditions and backgrounds are vital. If image diagnosis using AI can indeed ensure a more detailed diagnosis, such as breast cancer subtypes or prognosis, it can help develop personalized medicine, which is urgently required. The positive results of AI research, using such image information, can make each modality more valuable than ever. The current review summarized the results of previous studies using AI in each evaluation field and discussed the related future prospects.

ViT-MAENB7: An innovative breast cancer diagnosis model from 3D mammograms using advanced segmentation and classification process.

Tumors are an important health concern in modern times. Breast cancer is one of the most prevalent causes of death for women. Breast cancer is rapidly becoming the leading cause of mortality among women globally. Early detection of breast cancer allows patients to obtain appropriate therapy, increasing their probability of survival. The adoption of 3-Dimensional (3D) mammography for the medical identification of abnormalities in the breast reduced the number of deaths dramatically. Classification and accurate detection of lumps in the breast in 3D mammography is especially difficult due to factors such as inadequate contrast and normal fluctuations in tissue density. Several Computer-Aided Diagnosis (CAD) solutions are under development to help radiologists accurately classify abnormalities in the breast. In this paper, a breast cancer diagnosis model is implemented to detect breast cancer in cancer patients to prevent death rates. The 3D mammogram images are gathered from the internet. Then, the gathered images are given to the preprocessing phase. The preprocessing is done using a median filter and image scaling method. The purpose of the preprocessing phase is to enhance the quality of the images and remove any noise or artifacts that may interfere with the detection of abnormalities. The median filter helps to smooth out any irregularities in the images, while the image scaling method adjusts the size and resolution of the images for better analysis. Once the preprocessing is complete, the preprocessed image is given to the segmentation phase. The segmentation phase is crucial in medical image analysis as it helps to identify and separate different structures within the image, such as organs or tumors. This process involves dividing the preprocessed image into meaningful regions or segments based on intensity, color, texture, or other features. The segmentation process is done using Adaptive Thresholding with Region Growing Fusion Model (AT-RGFM)". This model combines the advantages of both thresholding and region-growing techniques to accurately identify and delineate specific structures within the image. By utilizing AT-RGFM, the segmentation phase can effectively differentiate between different parts of the image, allowing for more precise analysis and diagnosis. It plays a vital role in the medical image analysis process, providing crucial insights for healthcare professionals. Here, the Modified Garter Snake Optimization Algorithm (MGSOA) is used to optimize the parameters. It helps to optimize parameters for accurately identifying and delineating specific structures within medical images and also helps healthcare professionals in providing more precise analysis and diagnosis, ultimately playing a vital role in the medical image analysis process. MGSOA enhances the segmentation phase by effectively differentiating between different parts of the image, leading to more accurate results. Then, the segmented image is fed into the detection phase. The tumor detection is performed by the Vision Transformer-based Multiscale Adaptive EfficientNetB7 (ViT-MAENB7) model. This model utilizes a combination of advanced algorithms and deep learning techniques to accurately identify and locate tumors within the segmented medical image. By incorporating a multiscale adaptive approach, the ViT-MAENB7 model can analyze the image at various levels of detail, improving the overall accuracy of tumor detection. This crucial step in the medical image analysis process allows healthcare professionals to make more informed decisions regarding patient treatment and care. Here, the created MGSOA algorithm is used to optimize the parameters for enhancing the performance of the model. The suggested breast cancer diagnosis performance is compared to conventional cancer diagnosis models and it showed high accuracy. The accuracy of the developed MGSOA-ViT-MAENB7 is 96.6 %, and others model like RNN, LSTM, EffNet, and ViT-MAENet given the accuracy to be 90.31 %, 92.79 %, 94.46 % and 94.75 %. The developed model's ability to analyze images at multiple scales, combined with the optimization provided by the MGSOA algorithm, results in a highly accurate and efficient system for detecting tumors in medical images. This cutting-edge technology not only improves the accuracy of diagnosis but also helps healthcare professionals tailor treatment plans to individual patients, ultimately leading to better outcomes. By outperforming traditional cancer diagnosis models, the proposed model is revolutionizing the field of medical imaging and setting a new standard for precision and effectiveness in healthcare.

All-in-One Fusogenic Nanoreactor for the Rapid Detection of Exosomal MicroRNAs for Breast Cancer Diagnosis.

Molecular-profiling-based cancer diagnosis has significant implications for predicting disease prognosis and selecting targeted therapeutic interventions. The analysis of cancer-derived extracellular vesicles (EVs) provides a noninvasive and sequential method to assess the molecular landscape of cancer. Here, we developed an all-in-one fusogenic nanoreactor (FNR) encapsulating DNA-fueled molecular machines (DMMs) for the rapid and direct detection of EV-associated microRNAs (EV miRNAs) in a single step. This platform was strategically designed to interact selectively with EVs and induce membrane fusion under a specific trigger. After fusion, the DMMs recognized the target miRNA and initiated nonenzymatic signal amplification within a well-defined reaction volume, thus producing an amplified fluorescent signal within 30 min. We used the FNRs to analyze the unique expression levels of three EV miRNAs in various biofluids, including cell culture, urine, and plasma, and obtained an accuracy of 86.7% in the classification of three major breast cancer (BC) cell lines and a diagnostic accuracy of 86.4% in the distinction between patients with cancer and healthy donors. Notably, a linear discriminant analysis revealed that increasing the number of miRNAs from one to three improved the accuracy of BC patient discrimination from 78.8 to 95.4%. Therefore, this all-in-one diagnostic platform performs nondestructive EV processing and signal amplification in one step, providing a straightforward, accurate, and effective individual EV miRNA analysis strategy for personalized BC treatment.

Biomarker profiling and integrating heterogeneous models for enhanced multi-grade breast cancer prognostication.

BACKGROUND: Breast cancer remains a leading cause of female mortality worldwide, exacerbated by limited awareness, inadequate screening resources, and treatment options. Accurate and early diagnosis is crucial for improving survival rates and effective treatment. OBJECTIVES: This study aims to develop an innovative artificial intelligence (AI) based model for predicting breast cancer and its various histopathological grades by integrating multiple biomarkers and subject age, thereby enhancing diagnostic accuracy and prognostication. METHODS: A novel ensemble-based machine learning (ML) framework has been introduced that integrates three distinct biomarkers-beta-human chorionic gonadotropin (ß-hCG), Programmed Cell Death Ligand 1 (PD-L1), and alpha-fetoprotein (AFP)-alongside subject age. Hyperparameter optimization was performed using the Particle Swarm Optimization (PSO) algorithm, and minority oversampling techniques were employed to mitigate overfitting. The model's performance was validated through rigorous five-fold cross-validation. RESULTS: The proposed model demonstrated superior performance, achieving a 97.93% accuracy and a 98.06% F1-score on meticulously labeled test data across diverse age groups. Comparative analysis showed that the model outperforms state-of-the-art approaches, highlighting its robustness and generalizability. CONCLUSION: By providing a comprehensive analysis of multiple biomarkers and effectively predicting tumor grades, this study offers a significant advancement in breast cancer screening, particularly in regions with limited medical resources. The proposed framework has the potential to reduce breast cancer mortality rates and improve early intervention and personalized treatment strategies.

Patient-reported observations on medical procedure timeliness (PROMPT) in breast cancer: a qualitative study.

PURPOSE: Timeliness of care is an important healthcare outcome measure. The objective of this study was to explore patient perspectives on the timeliness of breast cancer diagnosis and treatment at accredited breast cancer centers. METHODS: In this qualitative study, 1 hour virtual interviews were conducted with participants 18-75 years old who were diagnosed and treated for stage 0-III breast cancer at a National Accreditation Program for Breast Centers facility from 2018 to 2022. Thematic analysis was used to identify key themes of participant experiences. RESULTS: Twenty-eight participants were interviewed. Two thematic domains were identified: etiologies of expedited or delayed care and the impact of delayed or expedited care on patients. Within these domains, multiple themes emerged. For etiologies of expedited or delayed care, participants discussed (1) the effect of scheduling appointments, (2) the COVID-19 pandemic, (3) dissatisfaction with the timeline for various parts of the diagnostic workup, and (4) delays related to patient factors, including socioeconomic status. For the impact of expedited or delayed care, patients discussed (1) the emotional and mental impact of waiting, (2) the importance of communication and clear expectations, and (3) the impact of electronic health portals. Patients desired each care interval (e.g., the time from mammogram to breast biopsy) to be approximately 7 days, with longer intervals sometimes preferred prior to surgery. CONCLUSION: These patient interviews identify areas of delay and provide patient-centered, actionable items to improve the timeliness of breast cancer care.

The luminescent Nb2C MXene nanosheet-based whispering gallery mode-enhanced ECL strategy for miRNA-214 detection.

MiRNA-214 can regulate the expression of their downstream target genes after post-transcriptional and are involved in the biological processes of triple negative breast cancer (TNBC). In this work, the small-sized luminescent Nb2C nanosheet-based whispering gallery mode-enhanced electrochemiluminescence (ECL) strategy was successfully constructed to detect miRNA-214 in TNBC. Firstly, we have synthesized small-sized luminescent Nb2C nanosheets from Nb2AlC MXene. The Nb2C nanosheets not only exhibited more stable chemical properties and reduced the defects of the large sheet structures, but also possessed the quantum confinement effect with the discrete energy level. As a result, the prepared small-sized Nb2C nanosheets had unique luminescent and electrochemical properties. Furthermore, in order to improve the ECL performance of Nb2C nanosheets, SiO2 microspheres were self-assembled on the electrode surface by gas-liquid interface method to form whispering gallery mode structure. Because the light was continuously reflected at the interface of the microcavity in the whispering gallery mode, the ECL signal of Nb2C luminescent nanosheets was amplified largely. Finally, the whispering gallery mode-based ECL sensing platform was established. The results showed that the biosensor had a good linear correlation between the ECL intensity and the logarithm of concentration of miRNA-214 in the range of 10 fM to 100 nM with a limit of detection of 2.5 fM. The actual detection of miRNA-214 content in clinical TNBC tissue samples was realized successfully.

Ensemble Deep Learning-Based Image Classification for Breast Cancer Subtype and Invasiveness Diagnosis from Whole Slide Image Histopathology.

Cancer diagnosis and classification are pivotal for effective patient management and treatment planning. In this study, a comprehensive approach is presented utilizing ensemble deep learning techniques to analyze breast cancer histopathology images. Our datasets were based on two widely employed datasets from different centers for two different tasks: BACH and BreakHis. Within the BACH dataset, a proposed ensemble strategy was employed, incorporating VGG16 and ResNet50 architectures to achieve precise classification of breast cancer histopathology images. Introducing a novel image patching technique to preprocess a high-resolution image facilitated a focused analysis of localized regions of interest. The annotated BACH dataset encompassed 400 WSIs across four distinct classes: Normal, Benign, In Situ Carcinoma, and Invasive Carcinoma. In addition, the proposed ensemble was used on the BreakHis dataset, utilizing VGG16, ResNet34, and ResNet50 models to classify microscopic images into eight distinct categories (four benign and four malignant). For both datasets, a five-fold cross-validation approach was employed for rigorous training and testing. Preliminary experimental results indicated a patch classification accuracy of 95.31% (for the BACH dataset) and WSI image classification accuracy of 98.43% (BreakHis). This research significantly contributes to ongoing endeavors in harnessing artificial intelligence to advance breast cancer diagnosis, potentially fostering improved patient outcomes and alleviating healthcare burdens.

BC-QNet: A quantum-infused ELM model for breast cancer diagnosis.

The timely and accurate diagnosis of breast cancer is pivotal for effective treatment, but current automated mammography classification methods have their constraints. In this study, we introduce an innovative hybrid model that marries the power of the Extreme Learning Machine (ELM) with FuNet transfer learning, harnessing the potential of the MIAS dataset. This novel approach leverages an Enhanced Quantum-Genetic Binary Grey Wolf Optimizer (Q-GBGWO) within the ELM framework, elevating its performance. Our contributions are twofold: firstly, we employ a feature fusion strategy to optimize feature extraction, significantly enhancing breast cancer classification accuracy. The proposed methodological motivation stems from optimizing feature extraction for improved breast cancer classification accuracy. The Q-GBGWO optimizes ELM parameters, demonstrating its efficacy within the ELM classifier. This innovation marks a considerable advancement beyond traditional methods. Through comparative evaluations against various optimization techniques, the exceptional performance of our Q-GBGWO-ELM model becomes evident. The classification accuracy of the model is exceptionally high, with rates of 96.54 % for Normal, 97.24 % for Benign, and 98.01 % for Malignant classes. Additionally, the model demonstrates a high sensitivity with rates of 96.02 % for Normal, 96.54 % for Benign, and 97.75 % for Malignant classes, and it exhibits impressive specificity with rates of 96.69 % for Normal, 97.38 % for Benign, and 98.16 % for Malignant classes. These metrics are reflected in its ability to classify three different types of breast cancer accurately. Our approach highlights the innovative integration of image data, deep feature extraction, and optimized ELM classification, marking a transformative step in advancing early breast cancer detection and enhancing patient outcomes.

Real-time breast lesion classification combining diffuse optical tomography frequency domain data and BI-RADS assessment.

Ultrasound (US)-guided diffuse optical tomography (DOT) has demonstrated potential for breast cancer diagnosis, in which real-time or near real-time diagnosis with high accuracy is desired. However, DOT's relatively slow data processing and image reconstruction speeds have hindered real-time diagnosis. Here, we propose a real-time classification scheme that combines US breast imaging reporting and data system (BI-RADS) readings and DOT frequency domain measurements. A convolutional neural network is trained to generate malignancy probability scores from DOT measurements. Subsequently, these scores are integrated with BI-RADS assessments using a support vector machine classifier, which then provides the final diagnostic output. An area under the receiver operating characteristic curve of 0.978 is achieved in distinguishing between benign and malignant breast lesions in patient data without image reconstruction.

Revolutionizing Breast Cancer Diagnosis: A Concatenated Precision through Transfer Learning in Histopathological Data Analysis.

Breast cancer remains a significant global public health concern, emphasizing the critical role of accurate histopathological analysis in diagnosis and treatment planning. In recent years, the advent of deep learning techniques has showcased notable potential in elevating the precision and efficiency of histopathological data analysis. The proposed work introduces a novel approach that harnesses the power of Transfer Learning to capitalize on knowledge gleaned from pre-trained models, adapting it to the nuanced landscape of breast cancer histopathology. Our proposed model, a Transfer Learning-based concatenated model, exhibits substantial performance enhancements compared to traditional methodologies. Leveraging well-established pretrained models such as VGG-16, MobileNetV2, ResNet50, and DenseNet121-each Convolutional Neural Network architecture designed for classification tasks-this study meticulously tunes hyperparameters to optimize model performance. The implementation of a concatenated classification model is systematically benchmarked against individual classifiers on histopathological data. Remarkably, our concatenated model achieves an impressive training accuracy of 98%. The outcomes of our experiments underscore the efficacy of this four-level concatenated model in advancing the accuracy of breast cancer histopathological data analysis. By synergizing the strengths of deep learning and transfer learning, our approach holds the potential to augment the diagnostic capabilities of pathologists, thereby contributing to more informed and personalized treatment planning for individuals diagnosed with breast cancer. This research heralds a promising stride toward leveraging cutting-edge technology to refine the understanding and management of breast cancer, marking a significant advancement in the intersection of artificial intelligence and healthcare.

3D Superclusters with Hybrid Bioinks for Early Detection in Breast Cancer.

The surface-enhanced Raman scattering (SERS) technique has garnered significant interest due to its ultrahigh sensitivity, making it suitable for addressing the growing demand for disease diagnosis. In addition to its sensitivity and uniformity, an ideal SERS platform should possess characteristics such as simplicity in manufacturing and low analyte consumption, enabling practical applications in complex diagnoses including cancer. Furthermore, the integration of machine learning algorithms with SERS can enhance the practical usability of sensing devices by effectively classifying the subtle vibrational fingerprints produced by molecules such as those found in human blood. In this study, we demonstrate an approach for early detection of breast cancer using a bottom-up strategy to construct a flexible and simple three-dimensional (3D) plasmonic cluster SERS platform integrated with a deep learning algorithm. With these advantages of the 3D plasmonic cluster, we demonstrate that the 3D plasmonic cluster (3D-PC) exhibits a significantly enhanced Raman intensity through detection limit down to 10-6 M (femtomole-(10-17 mol)) for p-nitrophenol (PNP) molecules. Afterward, the plasma of cancer subjects and healthy subjects was used to fabricate the bioink to build 3D-PC structures. The collected SERS successfully classified into two clusters of cancer subjects and healthy subjects with high accuracy of up to 93%. These results highlight the potential of the 3D plasmonic cluster SERS platform for early breast cancer detection and open promising avenues for future research in this field.

Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis.

PURPOSE: Serum microRNA (miRNA) holds great potential as a non-invasive biomarker for diagnosing breast cancer (BrC). However, most diagnostic models rely on the absolute expression levels of miRNAs, which are susceptible to batch effects and challenging for clinical transformation. Furthermore, current studies on liquid biopsy diagnostic biomarkers for BrC mainly focus on distinguishing BrC patients from healthy controls, needing more specificity assessment. METHODS: We collected a large number of miRNA expression data involving 8465 samples from GEO, including 13 different cancer types and non-cancer controls. Based on the relative expression orderings (REOs) of miRNAs within each sample, we applied the greedy, LASSO multiple linear regression, and random forest algorithms to identify a qualitative biomarker specific to BrC by comparing BrC samples to samples of other cancers as controls. RESULTS: We developed a BrC-specific biomarker called 7-miRPairs, consisting of seven miRNA pairs. It demonstrated comparable classification performance in our analyzed machine learning algorithms while requiring fewer miRNA pairs, accurately distinguishing BrC from 12 other cancer types. The diagnostic performance of 7-miRPairs was favorable in the training set (accuracy = 98.47%, specificity = 98.14%, sensitivity = 99.25%), and similar results were obtained in the test set (accuracy = 97.22%, specificity = 96.87%, sensitivity = 98.02%). KEGG pathway enrichment analysis of the 11 miRNAs within the 7-miRPairs revealed significant enrichment of target mRNAs in pathways associated with BrC. CONCLUSION: Our study provides evidence that utilizing serum miRNA pairs can offer significant advantages for BrC-specific diagnosis in clinical practice by directly comparing serum samples with BrC to other cancer types.

Triple assessment breast clinics: The value of clinical core biopsies.

BACKGROUND: Triple Assessment Breast Clinics are designed for rapid diagnosis of symptomatic patients. When there is no concordance between clinical and radiological assessment, clinicians perform clinical core biopsies. In patients with a clinically suspicious examination (S4, S5) and normal imaging, clinically guided core biopsy should be performed as per NCCP guidelines. However, substantial research does not exist on the diagnostic value or use of clinical core biopsies in non-suspicious palpable (S3) lesions and practices differ in each health system. AIMS: The aim of this research was to assess the diagnostic value of clinical core biopsies in nonsuspicious, probably benign palpable breast lesions (S3) where image guided cores were not indicated (R1/R2). METHODS: The cohort consisted of patients undergoing clinical core biopsies at a Symptomatic Breast Unit from January 2014 to 2019. Data regarding patient demographics, outcome of triple-assessment and incidence of malignancy were obtained from a prospectively maintained database and results were analysed using Minitab 2018. RESULTS: Three hundred and sixty patients had a clinical core biopsy performed in this period. Clinical examination scores for these patients were S1/S2 (66), S3 (277), S4 (15), and S5 (2). Radiology Scores were R1/R2 (355) and R3(5). Two patients with clinical score S3 (0.6%) were diagnosed with breast cancer due to their clinical cores. Both patients had normal mass imaging. There was no association between uncertain palpable breast lesions (S3), and atypia or malignancy on biopsy results when breast imaging was normal (P = 0.43, χ2 test). CONCLUSION: Despite clinical core biopsies being used in triple assessment, there is no certainty in their value except that there is high clinical suspicion. Imaging modalities are constantly improving and are already well established. When the patient is assigned a clinical score of S3 and has normal radiology, a clinical core biopsy is not required in most cases.

The Japanese breast cancer society clinical practice guidelines for breast cancer screening and diagnosis, 2022 edition.

This article provides updates to readers based on the newly published Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2022 Edition. These guidelines incorporate the latest evaluation of evidence from studies of diagnostic accuracy. For each clinical question, outcomes for benefits and harms were established, and qualitative or quantitative systematic reviews were conducted. Recommendations were determined through voting by a multidisciplinary group, and guidelines were documented to facilitate shared decision-making among patients and medical professionals. The guidelines address screening, surveillance, and pre- and postoperative diagnosis of breast cancer. In an environment that demands an integrated approach, decisions are needed on how to utilize modalities, such as mammography, ultrasound, MRI, and PET/CT. Additionally, it is vital to understand the appropriate use of new technologies, such as tomosynthesis, elastography, and contrast-enhanced ultrasound, and to consider how best to adapt these methods for individual patients.

Unveiling the future of breast cancer assessment: a critical review on generative adversarial networks in elastography ultrasound.

Elastography Ultrasound provides elasticity information of the tissues, which is crucial for understanding the density and texture, allowing for the diagnosis of different medical conditions such as fibrosis and cancer. In the current medical imaging scenario, elastograms for B-mode Ultrasound are restricted to well-equipped hospitals, making the modality unavailable for pocket ultrasound. To highlight the recent progress in elastogram synthesis, this article performs a critical review of generative adversarial network (GAN) methodology for elastogram generation from B-mode Ultrasound images. Along with a brief overview of cutting-edge medical image synthesis, the article highlights the contribution of the GAN framework in light of its impact and thoroughly analyzes the results to validate whether the existing challenges have been effectively addressed. Specifically, This article highlights that GANs can successfully generate accurate elastograms for deep-seated breast tumors (without having artifacts) and improve diagnostic effectiveness for pocket US. Furthermore, the results of the GAN framework are thoroughly analyzed by considering the quantitative metrics, visual evaluations, and cancer diagnostic accuracy. Finally, essential unaddressed challenges that lie at the intersection of elastography and GANs are presented, and a few future directions are shared for the elastogram synthesis research.

State-of-the-Art of Breast Cancer Diagnosis in Medical Images via Convolutional Neural Networks (CNNs).

Early detection of breast cancer is crucial for a better prognosis. Various studies have been conducted where tumor lesions are detected and localized on images. This is a narrative review where the studies reviewed are related to five different image modalities: histopathological, mammogram, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) images, making it different from other review studies where fewer image modalities are reviewed. The goal is to have the necessary information, such as pre-processing techniques and CNN-based diagnosis techniques for the five modalities, readily available in one place for future studies. Each modality has pros and cons, such as mammograms might give a high false positive rate for radiographically dense breasts, while ultrasounds with low soft tissue contrast result in early-stage false detection, and MRI provides a three-dimensional volumetric image, but it is expensive and cannot be used as a routine test. Various studies were manually reviewed using particular inclusion and exclusion criteria; as a result, 91 recent studies that classify and detect tumor lesions on breast cancer images from 2017 to 2022 related to the five image modalities were included. For histopathological images, the maximum accuracy achieved was around 99 %, and the maximum sensitivity achieved was 97.29 % by using DenseNet, ResNet34, and ResNet50 architecture. For mammogram images, the maximum accuracy achieved was 96.52 % using a customized CNN architecture. For MRI, the maximum accuracy achieved was 98.33 % using customized CNN architecture. For ultrasound, the maximum accuracy achieved was around 99 % by using DarkNet-53, ResNet-50, G-CNN, and VGG. For CT, the maximum sensitivity achieved was 96 % by using Xception architecture. Histopathological and ultrasound images achieved higher accuracy of around 99 % by using ResNet34, ResNet50, DarkNet-53, G-CNN, and VGG compared to other modalities for either of the following reasons: use of pre-trained architectures with pre-processing techniques, use of modified architectures with pre-processing techniques, use of two-stage CNN, and higher number of studies available for Artificial Intelligence (AI)/machine learning (ML) researchers to reference. One of the gaps we found is that only a single image modality is used for CNN-based diagnosis; in the future, a multiple image modality approach can be used to design a CNN architecture with higher accuracy.

Designing a Deep Learning-Driven Resource-Efficient Diagnostic System for Metastatic Breast Cancer: Reducing Long Delays of Clinical Diagnosis and Improving Patient Survival in Developing Countries.

Breast cancer is one of the leading causes of cancer mortality. Breast cancer patients in developing countries, especially sub-Saharan Africa, South Asia, and South America, suffer from the highest mortality rate in the world. One crucial factor contributing to the global disparity in mortality rate is long delay of diagnosis due to a severe shortage of trained pathologists, which consequently has led to a large proportion of late-stage presentation at diagnosis. To tackle this critical healthcare disparity, we have developed a deep learning-based diagnosis system for metastatic breast cancer that can achieve high diagnostic accuracy as well as computational efficiency and mobile readiness suitable for an under-resourced environment. We evaluated 4 Convolutional Neural Network (CNN) architectures: MobileNetV2, VGG16, ResNet50 and ResNet101. The MobileNetV2-based diagnostic model outperformed the more complex VGG16, ResNet50 and ResNet101 models in diagnostic accuracy, model generalization, and model training efficiency. The ROC AUC of MobilenetV2 (0.933, 95% CI: 0.930, 0.936) was higher than VGG16 (0.911, 95% CI: 0.908, 0.915), ResNet50 (0.869, 95% CI: 0.866, 0.873), and ResNet101 (0.873, 95% CI: 0.869, 0.876). The time per inference step for the MobileNetV2 model (15 ms/step) was substantially lower than that of VGG16 (48 ms/step), ResNet50 (37 ms/step), and ResNet110 (56 ms/step). The visual comparisons between the model prediction and ground truth have demonstrated that the MobileNetV2 diagnostic models can identify very small cancerous nodes embedded in a large area of normal cells which is challenging for manual image analysis. Equally Important, the light weight MobleNetV2 models were computationally efficient and ready for mobile devices or devices of low computational power. These advances empower the development of a resource-efficient and high performing AI-based metastatic breast cancer diagnostic system that can adapt to under-resourced healthcare facilities in developing countries.

Applying dual models on optimized LSTM with U-net segmentation for breast cancer diagnosis using mammogram images.

BACKGROUND OF THE STUDY: Breast cancer is the most fatal disease that widely affects women. When the cancerous lumps grow from the cells of the breast, it causes breast cancer. Self-analysis and regular medical check-ups help for detecting the disease earlier and enhance the survival rate. Hence, an automated breast cancer detection system in mammograms can assist clinicians in the patient's treatment. In medical techniques, the categorization of breast cancer becomes challenging for investigators and researchers. The advancement in deep learning approaches has established more attention to their advantages to medical imaging issues, especially for breast cancer detection. AIM: The research work plans to develop a novel hybrid model for breast cancer diagnosis with the support of optimized deep-learning architecture. METHODS: The required images are gathered from the benchmark datasets. These collected datasets are used in three pre-processing approaches like "Median Filtering, Histogram Equalization, and morphological operation", which helps to remove unwanted regions from the images. Then, the pre-processed images are applied to the Optimized U-net-based tumor segmentation phase for obtaining accurate segmented results along with the optimization of certain parameters in U-Net by employing "Adapted-Black Widow Optimization (A-BWO)". Further, the detection is performed in two different ways that is given as model 1 and model 2. In model 1, the segmented tumors are used to extract the significant patterns with the help of the "Gray-Level Co-occurrence Matrix (GLCM) and Local Gradient pattern (LGP)". Further, these extracted patterns are utilized in the "Dual Model accessed Optimized Long Short-Term Memory (DM-OLSTM)" for performing breast cancer detection and the detected score 1 is obtained. In model 2, the same segmented tumors are given into the different variants of CNN, such as "VGG19, Resnet150, and Inception". The extracted deep features from three CNN-based approaches are fused to form a single set of deep features. These fused deep features are inserted into the developed DM-OLSTM for getting the detected score 2 for breast cancer diagnosis. In the final phase of the hybrid model, the score 1 and score 2 obtained from model 1 and model 2 are averaged to get the final detection output. RESULTS: The accuracy and F1-score of the offered DM-OLSTM model are achieved at 96 % and 95 %. CONCLUSION: Experimental analysis proves that the recommended methodology achieves better performance by analyzing with the benchmark dataset. Hence, the designed model is helpful for detecting breast cancer in real-time applications.

Developing a weakly supervised deep learning framework for breast cancer diagnosis with HR status based on mammography images.

The status of hormone receptors (HR) at the molecular level is crucial for accurate diagnosis and effective treatment of breast cancer. Meanwhile, mammography is an effective screening method for detecting breast cancer, which significantly improve survival. However, diagnosing the molecular status of breast cancer involves a pathological biopsy, which can affect the accuracy of the diagnosis. To non-invasively diagnose the hormone receptor (HR) status of breast cancer and reduced manual annotation, we proposed a weakly supervised deep learning framework BSNet which detected breast cancer with HR status and benign tumors. BSNet was trained on 2321 multi-view mammography cases from female undergoing digital mammography for the general population at Harbin Medical University Cancer Hospital in Heilongjiang Province during the period 2017-2018 and was validated on the external cohort. The average AUCs of BSNet on the test set and the external validation set were 0.89 and 0.92, respectively. BSNet demonstrated excellent performance in non-invasive breast cancer diagnosis with HR status, using multiple mammography views without pixel annotation. Furthermore, we developed a web server (http://bsnet.edbc.org) for easy use. BSNet described high-dimensional mammography of breast cancer subtypes, which helped inform early management options.

ECL resonance energy transfer-regulated "off-on" mode biosensor for the detection of miRNA-150-5p in triple negative breast cancer.

MiRNAs played critical roles in triple negative breast cancer (TNBC) as potential biomarkers. Herein, an efficient signal "off-on" mode-biosensor based on electrochemiluminescence resonance energy transfer (ECL-RET) was successfully constructed for the miRNA-150-5p determination in TNBC. The ECL-RET regulated-sensing platform consisted of NiMn-LDHs nanoflowers, the artificially assembled phospholipid bilayers and hairpin DNA-labeled Eu-doped MoS2 QDs. Firstly, Eu-doped MoS2 QDs with high quantum efficiency were prepared as the ECL-RET donors. And NiMn-layer double hydroxides (LDHs) nanoflowers with wide UV-vis absorption spectra as the ECL-RET acceptors. Secondly, due to the hairpin DNA structure, the closed distance between ECL-RET donor-acceptor pair can quench the luminescence signal of Eu-doped MoS2 QDs. When miRNA-150-5p was captured, the hairpin DNA structure changed to a rodlike configuration and enlarged the distance between Eu-doped MoS2 QDs and NiMn-LDHs. As a result, the recovery of ECL signal can be observed as a signal "turn off-on" mode. Furthermore, the hydrophilicity of the lipid bilayer can reduce the nonspecific adsorption and improve the flexibility of the hairpin DNA efficiently. Therefore, based on the ECL-RET regulation strategy, the biosensor was employed to detect miRNA-150-5p from 10 fM to 1 nM with a detection limit of 1.5 fM. The constructed biosensor can effectively differentiate TNBC patient tumor and healthy breast fibroadenoma. The ECL-RET regulation strategy provided a new biosensing pathway for ultrasensitive detection of biomolecules and promoted the development of diagnosis and treatment of TNBC.